Immune-Related Adverse Events: Symptoms, Causes & Treatment

Immune-related adverse events, commonly called irAEs, are side effects that occur when cancer immunotherapy drugs accidentally turn the immune system against the body’s own healthy tissues. These events can affect virtually any organ, from skin rashes and thyroid dysfunction to life-threatening inflammation of the heart or lungs, and they develop in a significant fraction of patients receiving immune checkpoint inhibitors. Understanding what to look for, when symptoms tend to appear, and how they are managed can make a real difference in outcomes for the growing number of cancer patients treated with these drugs.

How Checkpoint Inhibitors Trigger These Reactions

Immune checkpoint inhibitors work by releasing the brakes on the immune system so it can attack cancer cells more aggressively. The drugs target proteins like CTLA-4, PD-1, or PD-L1, which normally act as “off switches” that prevent immune cells from becoming overactive. Blocking those switches is what makes the treatment effective against tumors, but it also removes safeguards that protect healthy tissues from immune attack.

Most irAEs are driven by activated T cells that lose their ability to distinguish cancer from normal tissue, or by B cells that start producing antibodies against the body’s own proteins.¹ Changes in T cell populations happen early after treatment begins, but the actual toxicity often shows up weeks or months later, suggesting that harmful immune cell populations gradually expand from the broader pool of newly activated cells.² Researchers have found that these reactions share both similarities and differences with naturally occurring autoimmune diseases like type 1 diabetes, rheumatoid arthritis, and Hashimoto’s thyroiditis, which means studying them side by side is helping scientists understand what keeps the immune system in check under normal circumstances.

The type of checkpoint inhibitor matters. Drugs targeting CTLA-4, such as ipilimumab, tend to cause more severe side effects overall, with serious (grade 3 or 4) reactions occurring in roughly 31% of patients, compared to about 10% for PD-1 inhibitors.³ The specific organs affected also differ by drug class. CTLA-4 blockers are more likely to cause colitis, pituitary gland inflammation, and skin rash, while PD-1 blockers are more associated with pneumonitis, thyroid problems, joint pain, and the skin condition vitiligo.³ Combination therapy using both types raises the risk further.

Skin Reactions Are Usually the First to Appear

The skin is the most commonly affected organ, and cutaneous irAEs are often the earliest sign that the immune system has been broadly activated. The most frequent skin reactions include a flat, red, bumpy rash (called maculopapular rash), itching, and eruptions that mimic psoriasis or lichen planus. These tend to appear within the first six weeks of treatment.⁴ Although the majority of skin reactions are mild to moderate, a small percentage become serious, including rare but dangerous conditions like Stevens-Johnson syndrome or drug reactions involving widespread skin and organ inflammation.⁵

A concern that has received more attention recently is that skin reactions can become chronic. A study characterizing long-lasting cutaneous irAEs found that about 85% were mild to moderate (grades 1–2), but 14% reached grade 3, and the range of presentations was broad: itching, rash resembling measles, dermatitis, blistering eruptions that look like the autoimmune disease bullous pemphigoid, and others.⁶ These chronic skin problems can persist long after immunotherapy has ended, which is a distinct quality-of-life concern we will return to later.

Gut, Endocrine, and Lung Involvement

After the skin, the gastrointestinal tract is one of the most frequently involved systems. Immune-mediated colitis, which causes diarrhea, abdominal pain, and sometimes bloody stools, has been reported in 35% to 50% of patients on checkpoint inhibitors, typically developing six to eight weeks after starting treatment.⁷ The severity of diarrhea alone does not reliably predict how bad the inflammation looks inside the colon; however, the presence of bloody stools does correlate with worse endoscopic findings.⁸ This distinction matters because it means oncology teams cannot rely solely on symptom severity to decide when to escalate treatment.

Endocrine irAEs are particularly common and often underappreciated. In one prospective study at a single center, about 40% of patients developed an endocrine side effect, with thyroid problems accounting for the vast majority and pituitary inflammation (hypophysitis) making up a smaller share.⁹ The median time to onset was about three months. Thyroid irAEs often start as a brief period of overactivity before settling into permanent underactivity requiring lifelong hormone replacement. Pituitary inflammation is rarer but carries lasting consequences: the resulting deficiency in the hormone ACTH, which controls cortisol production, is nearly always permanent.¹⁰

Immune-related pneumonitis, or lung inflammation, is less common but can be dangerous. It occurs more frequently with PD-1 inhibitors than CTLA-4 blockers. Imaging studies typically show one of several patterns, with an organizing pneumonia pattern being the most common, found in about half of cases, followed by a nonspecific interstitial pneumonia pattern in roughly a quarter.¹¹ Symptoms include new or worsening cough, shortness of breath, and chest pain. Whether the pneumonitis improves with treatment is an independent factor in survival, which underscores why early recognition and aggressive management matter.¹¹

Rare but High-Stakes Reactions

Cardiac and neurological irAEs are uncommon, but they carry outsized risk. Immune-related myocarditis, or inflammation of the heart muscle, occurs infrequently yet can be life-threatening, often developing shortly after treatment begins. Diagnosing it is tricky because the symptoms (fatigue, chest pain, shortness of breath, irregular heartbeat) overlap with many other conditions. Oncology teams rely on a combination of blood markers, heart tracings, imaging, and sometimes a tissue biopsy to confirm it.¹²

Neurological irAEs span a wide range, from mild peripheral nerve tingling to immune-related encephalitis, which involves brain inflammation. In cases of encephalitis, testing commonly reveals elevated white blood cells and protein in the spinal fluid, and about a third of patients show abnormalities on brain MRI.¹³ Because these reactions can mimic infections, strokes, and brain metastases, getting the right diagnosis quickly is essential.

What Affects Your Risk

Beyond the drug class, several factors influence whether and how severely a person develops irAEs. The gut microbiome has emerged as a particularly interesting player. Research has found that patients who developed colitis from combination checkpoint blockade had a significantly higher abundance of certain gut bacteria, and this bacterial signature was linked to increased inflammatory signaling in the gut lining.¹⁴ This has prompted exploration of whether manipulating the gut microbiome through fecal transplants or probiotics could reduce the risk of immune-related colitis.¹⁵

Despite intense research, there is currently no single blood test that reliably predicts who will develop irAEs before they happen. Multiple candidate biomarkers have been identified, including inflammatory markers like CRP and IL-6, blood cell counts, thyroid-stimulating hormone levels, and various genetic and immune cell signatures.¹⁶ However, much of this research comes from small, single-center studies that haven’t been validated more broadly.¹⁷ In everyday clinical practice, the only biomarker used routinely is thyroid-stimulating hormone for catching thyroid irAEs early.¹⁸ The field is moving toward composite scores that combine several markers, but none have been validated enough for widespread use yet.

First-Line Treatment With Steroids

The backbone of irAE management is corticosteroids, and the approach is graded to the severity of the reaction. Mild (grade 1) irAEs can sometimes be watched closely without stopping immunotherapy or adding treatment. Moderate (grade 2) reactions typically call for pausing the checkpoint inhibitor and starting oral steroids. For serious (grade 3) reactions, guidelines from the American Society of Clinical Oncology recommend suspending immunotherapy and beginning high-dose steroids, then tapering the dose gradually over at least four to six weeks.¹⁹ Tapering too quickly is a well-known mistake that can cause the irAE to flare back.

Grade 4 (life-threatening) reactions generally mean permanently discontinuing that particular checkpoint inhibitor. For organ-specific irAEs like myocarditis or severe pneumonitis, treatment escalation may begin even sooner. The grading system guides not just steroid dosing but the entire decision tree around whether to continue, pause, or stop cancer treatment.

When Steroids Are Not Enough

Roughly one in six patients who develop irAEs will need something beyond steroids. In a large analysis, about 16% of irAE cases required second-line therapy, and the options were diverse: TNF-alpha blockers like infliximab were used most often (in about 47% of second-line cases), followed by intravenous immunoglobulins and mycophenolate mofetil.²⁰ Infliximab tended to produce faster symptom improvement than the alternatives. The majority of steroid-resistant irAEs did eventually resolve or improve, though about 4% persisted and another 4% were fatal with ongoing symptoms.²⁰

For steroid-resistant colitis specifically, vedolizumab, a drug that targets gut-specific immune pathways, has shown promise. In one multi-center study, patients treated with vedolizumab achieved sustained clinical remission in 86% of cases.²¹ Even among patients who had already failed infliximab, vedolizumab still achieved a response rate of about 67%. Infliximab and vedolizumab achieved similar overall remission rates for immune-mediated colitis (around 88%), though vedolizumab took somewhat longer to produce a clinical response.²² An important reassurance from these studies is that tumor response rates in patients who needed second-line irAE therapy were similar to those in patients whose irAEs were controlled with steroids alone, meaning the additional immunosuppression did not appear to undermine the cancer treatment.

People With Pre-Existing Autoimmune Conditions

Patients who already have an autoimmune disease were historically excluded from most checkpoint inhibitor trials, leaving a gap in safety data that clinicians have had to fill through real-world experience. A systematic review found that about 54% of these patients experienced some grade of irAE, and about a third had flares of their pre-existing condition.²³ Some patients experienced both a new irAE and a flare at the same time. About 15% discontinued treatment because of toxicity. Crucially, treatment still worked for many of these patients, with response rates ranging from 11% to 50% depending on the disease and cancer type.

The risk is not uniform across autoimmune conditions. A cohort study focusing on neurological autoimmune diseases found that patients with myasthenia gravis had frequent and more severe exacerbations when given checkpoint inhibitors, while those with multiple sclerosis had few problems.²⁴ Survival did not appear to differ between the groups, suggesting that with the right monitoring, checkpoint inhibitors remain an option for many patients with autoimmune histories.

The Side-Effect Paradox

One of the more counterintuitive findings in this field is that patients who develop irAEs often have better cancer outcomes than those who do not. A systematic review and meta-analysis looking at melanoma found that patients who experienced irAEs lived roughly twice as long as those who did not, with a median overall survival of about 15 months versus 9 months.²⁵ The pattern held for lung cancer, where median overall survival was about 19 months in patients with irAEs compared to roughly 7.5 months without them. Tumor response rates were also roughly double in the irAE group across both cancer types. Similar trends were observed in kidney, bladder, and head and neck cancers.²⁵

The interpretation is that the same robust immune activation responsible for attacking normal tissue is also what makes the treatment effective against the tumor. This does not mean more side effects are better or that doctors should try to provoke them. It does, however, offer some reassurance to patients dealing with irAEs: the side effects may be a signal that the treatment is engaging the immune system forcefully.

Restarting Immunotherapy After a Serious Reaction

When a patient has a strong response to a checkpoint inhibitor but develops a serious irAE, the question of whether to try again is one of the most difficult decisions in oncology. The available evidence suggests that rechallenge is feasible for many patients, even those who had grade 3 or 4 reactions, but new or recurring toxicities should be expected.²⁶ Most of these recurrent side effects are manageable, particularly at centers with multidisciplinary experience in irAE management. Both restarting the same drug and switching to a different checkpoint inhibitor class have shown potential survival benefits, though patients with prior serious reactions need to be carefully assessed beforehand.²⁷

The risk calculus is highly individual. A patient whose only remaining treatment option is a checkpoint inhibitor and who had a manageable colitis episode is in a very different position from someone who developed myocarditis, where rechallenge carries a much higher danger. There is no blanket rule; the decision rests on the type and severity of the original irAE, whether it fully resolved, and what alternative treatments are available.

Pediatric Patients Face a Different Profile

Checkpoint inhibitors are increasingly being used in children, but the safety profile in this population looks somewhat different from adults. A pharmacovigilance analysis across two large global adverse event databases identified four categories of irAEs that were disproportionately reported in pediatric patients compared to adults: cytokine release syndrome, acute respiratory distress syndrome, seizures, and febrile neutropenia.²⁸ The mechanisms involved may include different patterns of immune activation, inflammatory signaling imbalance, and effects on the developing nervous system. This is still an area with limited data, and the evidence base is much thinner than it is for adults.

Lasting Effects on Quality of Life

While many irAEs resolve within weeks to months, a meaningful subset become chronic. Patients whose irAEs persist long after stopping immunotherapy report substantially lower quality of life. One study compared cancer survivors with chronic irAEs to those without and found clinically meaningful reductions in health-related quality-of-life scores across multiple measures.²⁹ Endocrine irAEs are a prime example: many patients with thyroid dysfunction or pituitary damage require hormone replacement indefinitely. Chronic skin conditions and joint pain also persist in some patients well beyond the treatment period.

Even among patients with severe irAEs that eventually resolve, the experience takes a toll. In a randomized trial of melanoma patients, those who had experienced grade 3 or 4 irAEs had lower average quality-of-life scores at both 24 and 48 weeks compared to those with milder or no side effects, though the differences did not reach statistical significance in that particular study.³⁰ The lack of statistical significance in one trial does not mean there is no effect; it may reflect the difficulty of capturing it in moderate-sized studies. The larger body of evidence consistently points toward a quality-of-life burden, especially for patients whose reactions linger.

The Financial Weight of irAEs

Beyond the physical and emotional burden, irAEs carry significant financial costs. When an irAE requires hospitalization, the expenses climb rapidly. One real-world analysis found that patients whose irAE led to an inpatient stay incurred mean costs of roughly $29,500, compared to about $5,700 for those managed as outpatients.³¹ The costliest irAEs by far were transverse myelitis (averaging about $81,000), toxic epidermal necrolysis (about $69,000), and myocarditis (about $45,000). At the other end, adrenal insufficiency and similar endocrine conditions were far less expensive to manage, though they may require lifelong medication.

Looking at the broader picture, adjusted six-month total costs were roughly $24,000 higher for patients who developed any adverse event compared to those who did not, and inpatient care accounted for the overwhelming majority of those costs, ranging from 79% to 91% depending on the cancer type.³² These numbers underscore why early detection and outpatient management of irAEs are not just clinical priorities but economic ones. Catching a reaction before it spirals into an emergency department visit or prolonged hospital stay saves both suffering and money.